Sanofi announces €44 million investment in Genzyme campus in Waterford
Published on: Thursday, 14 February 2013
Genzyme Waterford produces medicines for patients living with rare genetic diseases, kidney disease and cholesterol management requirements. Shipped to more than 70 countries, these include Myozyme ®, Lumizyme ®, Cerezyme ®, Thymoglobulin ®, Cholestagel ®, Renvela ® and Renagel ®. Following hard on the heels of a €150 million investment little more than a year ago, this investment of a further €44 million will increase the site’s diversity of products by adding the filling of Sanofi’s Lantus® (insulin glargine), the number one insulin brand worldwide. Subject to regulatory approvals, commercial production of Lantus® at Waterford should commence in 2016.
For further information, click here for the news item from IDA Ireland.